Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...
Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases ...
Nasdaq

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) ...
Nasdaq

Theriva Biologics Completes Enrollment in VIRAGE Phase 2b Trial of VCN-01 for Metastatic Pancreatic Cancer; Fast Track and Rare Disease Designations Secured

Theriva Biologics announced the completion of patient enrollment in its Phase 2b clinical trial called VIRAGE, which evaluates VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC), with ...
Seeking Alpha

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

- The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - Based on the current Phase 2b trial enrollment pace and the interim ...

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
Pharmabiz

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis: Ghent, Belgium Saturday, January 10, 2026, 16:00 Hrs [IST] MRM ...